Lung Cancer (NSCLC)

There remains interest to assess our lead product candidate in combination with Tarceva® for the treatment of NSCLC. The interest in combining our lead product candidate with an EGFR inhibitor was based on results, which we published in Investigational New Drugs recently, of treatment for non-small cell lung cancer patients who have previously been treated with an EGFR inhibitor. Patients receiving anti-EGFR therapy prior to our therapy had considerably better outcomes than those that had not received EGFR inhibition. We will continue to look for opportunities in combination therapy for non-small cell lung cancer and other indications involving anti EGFR treatment.

Relevant Publication